• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Basic and Clinical Research of p53 Gene Therapy for Human Cancer

Research Project

Project/Area Number 08671529
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Thoracic surgery
Research InstitutionOkayama University

Principal Investigator

INOUE Fumiyuki  Okayama University Medical School, First Department of Surgery, Assistant Professor, 医学部・附属病院, 講師 (90223271)

Co-Investigator(Kenkyū-buntansha) YASUDA Tatsuji  Okayama University Medical School, Department of Cell Biology, Institute of Cell, 医学部, 教授 (30092357)
FUJIWARA Toshiyoshi  Okayama University Medical School, First Department of Surgery, Instructor, 医学部, 助手 (00304303)
Project Period (FY) 1996 – 1997
Project Status Completed (Fiscal Year 1997)
Budget Amount *help
¥2,200,000 (Direct Cost: ¥2,200,000)
Fiscal Year 1997: ¥800,000 (Direct Cost: ¥800,000)
Fiscal Year 1996: ¥1,400,000 (Direct Cost: ¥1,400,000)
Keywordsp53 Gene / Antiangiogenesis / Lung Cancer / Gene Therapy / 非小細胞肺癌 / アデノウイルスベクター / 血管新生
Research Abstract

Angiogenesis is required for the growth and progression of malignancies. Recent studies have demonstrated that genetic alterations may accompany acquisition of the angiogenic phenotype. The tumor suppressor p53 gene is most frequently mutated in human cancers and is also known to be a transcriptional regulator of a variety of genes. Here we investigated the antiangiogenic effect of the wild-type p53 gene transfer on a human non-small-cell lung cancer cell line. Mutant p53-expressing H226Br NSCLC cells were transduced with the wild-type p53 gene using a recombinant adenoviral vector (Ad5CMVp53) and applied to semi-quantitative reverse transcription-polymerase chain reactions to detect altered mRNA expression of angiogenic and/or antiangiogenic factors. In vivo neovascularization assay of Ad5CMVp53-infected cells was then performed using a membrane-diffusion chamber system subcutaneously transplanted in nu/nu mice. We also evaluated the effect of Ad5CMVp53-infected H226Br cells on nontransduced tumor cells in vivo by subcutaneously inoculating mixture of cells into nu/nu mice. Ad5CMVp53 infection markedly inhibited the expression of an angiogenic factor, vascular endothelial growth factor (VEGF), and increased the expression of a novel antiangiogenic factor, brain-specific angiogenesis inhibitor 1 (BAI1), resulting in the reduced neovascularization in vivo. Mixing experiments showed that tumor cells transduced with the wild-type p53 gene inhibited the in vivo tumor growth of adjacent nontransduced cells. Our data suggest that a recombinant adenovirus expressing the wild-type p53 gene is antiangiogenic, which may explain in part the mechanism of the bystander effect induced by the wild-type p53 gene transfer on adjacent tumor cells.

Report

(3 results)
  • 1997 Annual Research Report   Final Research Report Summary
  • 1996 Annual Research Report
  • Research Products

    (8 results)

All Other

All Publications (8 results)

  • [Publications] Bouvet M: "Adenovirus-mediated wild-type p53 gene transfer downregulates vascular endotherial growth factor expression and inhibits anglogenesis in human colon cancer." Cancer Research. 58. 2288-2292 (1998)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1997 Final Research Report Summary
  • [Publications] Nishizaki M: "Antiangiogenic effect of recombinant adenovirus expressing the wild-type p53 gene: proposed mechanism for bystander effect." Clinical Cancer Research. in press. (1999)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1997 Final Research Report Summary
  • [Publications] Bouvet, M., Ellis, L.M., Nishizaki, M., Fujiwara, T., Liu, W., Bucana, C.D., Fang, B,Lee, J.J., Roth, J.A.: "Adenovirus-mediated Wild-type p53 gene transfer downregulates vascular endotherial growth factor expression and inhibits angiogenesis in human colon cancer." Cancer Research. 58. 2288-2292 (1998)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1997 Final Research Report Summary
  • [Publications] Nishizaki, M., Fujiwara, T., Tanida, T., Hizuta, A., Nishimori, H., Tokino, T., Nakamura, Y., Bouvet, M., Roth, J.A., Tanaka, N.: "Antiangiogenic effect of recombinant adenovirus expressing the wild-type p53 gene : proposed mechanism for bystander effect." Clinical Cancer Research. (in press). (1999)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1997 Final Research Report Summary
  • [Publications] Hamada,M.: "p53 is a potent determinant of chemosensitivity and radiosensitivity in human gastric and rectal cancers." J.Cancer Res.Clin.Oncol.122. 360-365 (1996)

    • Related Report
      1996 Annual Research Report
  • [Publications] 藤原俊義: "癌抑制遺伝子p53発現ウイルスベクターによる癌の遺伝子治療." Human Cell. 9. 25-30 (1996)

    • Related Report
      1996 Annual Research Report
  • [Publications] 藤原俊義: "胃癌・大腸癌のDNA障害性抗腫瘍治療における変異型p53発現の意義." 癌と化学療法. 23. 1081-1083 (1996)

    • Related Report
      1996 Annual Research Report
  • [Publications] 藤原俊義: "アデノウイルスベクターによる正常型p53遺伝子導入とCisplatin併用療法の有効性." 癌と化学療法. 23. 1085-1088 (1996)

    • Related Report
      1996 Annual Research Report

URL: 

Published: 1996-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi